Clinical Trials Search at Vanderbilt-Ingram Cancer Center
The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.
Panitumumab, Nivolumab, and Ipilimumab in Treating Patients with KRAS, NRAS, or BRAF Wild-Type MSS Refractory Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
This phase II trial studies how well panitumumab, nivolumab, and ipilimumab work in treating patients with KRAS, NRAS, or BRAF wild-type microsatellite stable (MSS) colorectal cancer that does not respond to treatment, has spread to other places in the body, and cannot be removed by surgery. Monoclonal antibodies, such as panitumumab, nivolumab, and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
Nivolumab after Combined Modality Therapy in Treating Patients with High Risk Stage II-IIIB Anal Cancer
This randomized phase II clinical trial studies how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
This study will evaluate the safety profile, tolerability, PK, PD, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab in participants with metastatic colorectal and pancreatic cancers.